T 0777/15 (Crystalline form of aripiprazole/OTSUKA) of 17.11.2020

European Case Law Identifier: ECLI:EP:BA:2020:T077715.20201117
Date of decision: 17 November 2020
Case number: T 0777/15
Petition for review of: -
Application number: 02782507.4
IPC class: A61P 25/18 A61K 31/496 C07D 215/22
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: LOW HYGROSCOPIC ARIPIPRAZOLE DRUG SUBSTANCE AND PROCESSES FOR THE PREPARATION THEREOF
Applicant name: OTSUKA PHARMACEUTICAL CO., LTD.
Opponent name: Teva Pharmaceutical Industries Ltd.
Fermion Oy
Pharmaceutical Works POLPHARMA
EGIS Gyógyszergyár Nyrt
Ratiopharm GmbH
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 108 (2007)European Patent Convention Art 113(2) (2007)European Patent Convention R 101(1) (2007)European Patent Convention R 103(4)(c)European Patent Convention R 134(2) (2007)European Patent Convention R 134(4) (2007)European Patent Convention R 99(2) (2007)
Keywords: Basis of decision - text or agreement to text withdrawn by patent proprietor
Basis of decision - patent revoked
Appellant-opponent 5: Admissibility of appeal - statement of grounds (not filed)
Appellant-opponent 5: partial reimbursement (no)
Appellant-opponent 2: partial reimbursement of appeal fee (yes) - 25%
Catchword: -
Cited cases: T 0073/84 T 0186/84 T 0507/00 T 0545/10 T 1258/16
Citing cases: J 0010/20 T 0191/17 T 2698/17 T 0488/18 T 0795/19

Order

For these reasons it is decided that:

1. The appeal of appellant-opponent 5 is rejected as inadmissible.

2. The decision under appeal is set aside.

3. The patent is revoked.

4. The appeal fee of appellant-opponent 2 is reimbursed at 25% pursuant to Rule 103(4)(c) EPC.